BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Aguado C, García-Paredes B, Sotelo MJ, Sastre J, Díaz-Rubio E. Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer? World J Gastroenterol 2014; 20(20): 6092-6101 [PMID: 24876731 DOI: 10.3748/wjg.v20.i20.6092]
URL: https://www.wjgnet.com/1007-9327/full/v20/i20/6092.htm
Number Citing Articles
1
Lucía Cortejoso, Xandra García-González, María I García, Pilar García-Alfonso, María Sanjurjo, Luis A López-Fernández. Cost–Effectiveness of Screening for DPYD Polymorphisms to Prevent Neutropenia in Cancer Patients Treated with Fluoropyrimidines Pharmacogenomics 2016; 17(9): 979 doi: 10.2217/pgs-2016-0006
2
Majed Alshamrani, Atika AlHarbi, Nora Alkhudair, Fouad AlNajjar, Mansoor Khan, Abdulaziz Ben Obaid, Amr Khardaly, Eshtyag Bajnaid, Hadeel Samarkandi, Aeshah AlAzmi, Salman Alabdali, Mohammed AlNahedh. Practical strategies to manage cancer patients during the COVID-19 pandemic: Saudi Oncology Pharmacy Assembly Experts recommendationsJournal of Oncology Pharmacy Practice 2020; 26(6): 1429 doi: 10.1177/1078155220935564
3
Maryam Naghsh-Nejad, Serena Yu, Philip Haywood. Provider responses to the expansion of public subsidies in healthcare: The case of oral chemotherapy treatment in AustraliaSocial Science & Medicine 2023; 330: 116041 doi: 10.1016/j.socscimed.2023.116041
4
VM Patil, S Chakraborty, TK Jithin, S Dessai, TP Sajith Babu, V Raghavan, M Geetha, TShiva Kumar, MS Biji, A Bhattacharjee, C Nair. Development and validation of a questionnaire to measure preferences and expectations of patients undergoing palliative chemotherapy: EXPECT questionnaireIndian Journal of Cancer 2016; 53(2): 339 doi: 10.4103/0019-509X.197735
5
Chengyi Mao, Xiaoxi Zeng, Chao Zhang, Yushang Yang, Xin Xiao, Siyuan Luan, Yonggang Zhang, Yong Yuan. Mechanisms of Pharmaceutical Therapy and Drug Resistance in Esophageal CancerFrontiers in Cell and Developmental Biology 2021; 9 doi: 10.3389/fcell.2021.612451
6
Dong-hyun Lee, Sin Seong, Yunsik Won. Traditional Korean medicine as second-line treatment of metastatic colorectal cancerMedicine: Case Reports and Study Protocols 2021; 2(2): e0042 doi: 10.1097/MD9.0000000000000042
7
Gary Mitchell, Sam Porter, Elizabeth Manias. From telling to sharing to silence: A longitudinal ethnography of professional‐patient communication about oral chemotherapy for colorectal cancerPsycho-Oncology 2019; 28(2): 336 doi: 10.1002/pon.4945
8
Jack T. Thompson, David M. Wood, Paul I. Dargan. Review of the fluoropyrimidine antidote uridine triacetateBritish Journal of Clinical Pharmacology 2024;  doi: 10.1111/bcp.16319
9
Jingjing Sha, Yunpeng Bai, Huy Xuan Ngo, Tatsuo Okui, Takahiro Kanno. Overview of Evidence-Based Chemotherapy for Oral Cancer: Focus on Drug Resistance Related to the Epithelial-Mesenchymal TransitionBiomolecules 2021; 11(6): 893 doi: 10.3390/biom11060893
10
Amit Sehrawat, Mridul Khanna, Smita Kayal, Deepak Sundriyal, Shraddha Tiwari, Sunu Cyriac, Praveen Ravishankaran, Jomon Raphael, Dominic Mathew, Soumya Surath Panda, Laltendu Moharana, Sumit Subhadarshi Mohanty, Swati Sucharita Mohanty, Ashwin Philips, Deepak Jain, Pamela Jeyaraj, Parvez Haque David, Jaineet Patil, S.V. Saju, Krishnakumar Rathnam, Neha Sharma, Kaaviya Dheva, Sree Rekha Jinkala, Kalyarasaran Raja, Prasanth Penumadu, Prasanth Ganesan. Clinicopathologic Profile and Treatment Outcomes of Colorectal Cancer in Young Adults: A Multicenter Study From IndiaJCO Global Oncology 2024; (10) doi: 10.1200/GO.23.00225
11
Jaleh Varshosaz, Sara Riahi, Erfaneh Ghassami, Ali Jahanian-Najafabadi. Transferrin-targeted poly(butylene adipate)/terephthalate nanoparticles for targeted delivery of 5-fluorouracil in HT29 colorectal cancer cell lineJournal of Bioactive and Compatible Polymers 2017; 32(5): 503 doi: 10.1177/0883911517690756
12
Diego Novick, Felice Leonardi, Daniel Lee Kay Pen, M. E. Montoya-Restrepo, Cristina Avendaño, Sara Siddi, Maria V. Moneta, J. M. Haro, Juan Carlos Velasquez. Retrospective analysis of patients with advanced or metastatic gastric cancer in ColombiaJournal of Medical Economics 2019; 22(9): 891 doi: 10.1080/13696998.2019.1617161
13
Elvida C. TAHIYA, Andi A. ISLAM, Mochammad HATTA, Ronald E. LUSIKOOY, Prihantono PRIHANTONO, Reno RUDIMAN, I K. WIDIANA, Ilhamjaya PATELONGI, Agus S. BUKHARI. 5-Fluorouracil for colorectal cancer: mechanism of action and metabolismGazzetta Medica Italiana Archivio per le Scienze Mediche 2024; 183(4) doi: 10.23736/S0393-3660.23.05249-X
14
Sona Vodenkova, Tomas Buchler, Klara Cervena, Veronika Veskrnova, Pavel Vodicka, Veronika Vymetalkova. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and futurePharmacology & Therapeutics 2020; 206: 107447 doi: 10.1016/j.pharmthera.2019.107447
15
Nedal Bukhari, Hani Al-Mohanna, Fahad Almsned. Thymidylate Synthase (TYMS) and Methylenetetrahydrofolate Reductase (MTHFR) Gene Polymorphisms Associated With Severe Capecitabine Toxicity: The First Case From Saudi ArabiaCureus 2023;  doi: 10.7759/cureus.49215
16
Amit K. Jain, Sanyog Jain. Advances in oral delivery of anti-cancer prodrugsExpert Opinion on Drug Delivery 2016; 13(12): 1759 doi: 10.1080/17425247.2016.1200554
17
Claire Palles, Susan Fotheringham, Laura Chegwidden, Marie Lucas, Rachel Kerr, Guy Mozolowski, Dan Rosmarin, Jenny C. Taylor, Ian Tomlinson, David Kerr. An Evaluation of the Diagnostic Accuracy of a Panel of Variants in DPYD and a Single Variant in ENOSF1 for Predicting Common Capecitabine Related ToxicitiesCancers 2021; 13(7): 1497 doi: 10.3390/cancers13071497
18
Reetu Mukherji, John L. Marshall. Lessons Learned in Managing Patients with Colorectal Cancer During the COVID-19 PandemicCurrent Treatment Options in Oncology 2021; 22(10) doi: 10.1007/s11864-021-00888-3
19
Yarden Ariav, James H Ch’ng, Heather R. Christofk, Noga Ron-Harel, Ayelet Erez. Targeting nucleotide metabolism as the nexus of viral infections, cancer, and the immune responseScience Advances 2021; 7(21) doi: 10.1126/sciadv.abg6165
20
Cátia Venâncio, Bruna Monteiro, Isabel Lopes, Ana C. A. Sousa. Assessing the risks of capecitabine and its active metabolite 5-fluorouracil to freshwater biotaEnvironmental Science and Pollution Research 2023; 30(20): 58841 doi: 10.1007/s11356-023-26505-4
21
Ruben Vardanyan, Victor Hruby. Synthesis of Best-Seller Drugs2016; : 495 doi: 10.1016/B978-0-12-411492-0.00028-6
22
Dan Zhang, Jiarui Wu, Kaihuan Wang, Xiaojiao Duan, Shi Liu, Bing Zhang. Which are the best Chinese herbal injections combined with XELOX regimen for gastric cancer?Medicine 2018; 97(12): e0127 doi: 10.1097/MD.0000000000010127
23
Gary Mitchell, Sam Porter, Elizabeth Manias. Enabling sustained communication with patients for safe and effective management of oral chemotherapy: A longitudinal ethnographyJournal of Advanced Nursing 2021; 77(2): 899 doi: 10.1111/jan.14634
24
William H. Gmeiner. Chemistry of Fluorinated Pyrimidines in the Era of Personalized MedicineMolecules 2020; 25(15): 3438 doi: 10.3390/molecules25153438
25
Michael Chahin, Nithya Krishnan, Hardik Chhatrala, Marwan Shaikh. A 5-Fluorouracil-Induced Hyperammonemic Encephalopathy Challenged with CapecitabineCase Reports in Oncological Medicine 2020; 2020: 1 doi: 10.1155/2020/4216752
26
Graciela Gigola, Pedro Carriere, María Belén Novoa Díaz, Gabriela Perdigon, Ariel Osvaldo Zwenger, Claudia Gentili. Survival effect of probiotics in a rat model of colorectal cancer treated with capecitabineWorld Journal of Gastrointestinal Oncology 2021; 13(10): 1518-1531 doi: 10.4251/wjgo.v13.i10.1518
27
Jia Luo, ZhouXue Wu, Yun Lu, Kang Xiong, Qian Wen, Ling Zhao, BiQiong Wang, Yan Gui, ShaoZhi Fu. Intraperitoneal administration of biocompatible hyaluronic acid hydrogel containing multi-chemotherapeutic agents for treatment of colorectal peritoneal carcinomatosisInternational Journal of Biological Macromolecules 2020; 152: 718 doi: 10.1016/j.ijbiomac.2020.02.326
28
M.B. Cristóvão, R. Janssens, A. Yadav, S. Pandey, P. Luis, B. Van der Bruggen, K.K. Dubey, M.K. Mandal, J.G. Crespo, V.J. Pereira. Predicted concentrations of anticancer drugs in the aquatic environment: What should we monitor and where should we treat?Journal of Hazardous Materials 2020; 392: 122330 doi: 10.1016/j.jhazmat.2020.122330